Tolerability of solifenacin and oxybutynin immediate release in older (>65 years) and younger (≤65 years) patients with overactive bladder: sub-analysis from a Canadian, randomized, double-blind study
| العنوان: | Tolerability of solifenacin and oxybutynin immediate release in older (>65 years) and younger (≤65 years) patients with overactive bladder: sub-analysis from a Canadian, randomized, double-blind study |
|---|---|
| المؤلفون: | Jack Barkin, E Hirshberg, Kevin V. Carlson, J Corcos, Jane Schulz, L Stothers, Harold P. Drutz, Peter Pommerville, B Egerdie, Sender Herschorn, Jerzy B. Gajewski, Sidney B. Radomski |
| المصدر: | Current Medical Research and Opinion. 27:375-382 |
| بيانات النشر: | Informa Healthcare, 2010. |
| سنة النشر: | 2010 |
| مصطلحات موضوعية: | Adult, Male, Solifenacin Succinate, Canada, Quinuclidines, medicine.medical_specialty, Urology, Muscarinic Antagonists, law.invention, Young Adult, Double-Blind Method, Meta-Analysis as Topic, Randomized controlled trial, law, Tetrahydroisoquinolines, medicine, Humans, Adverse effect, Oxybutynin, Aged, Aged, 80 and over, Dosage Forms, Solifenacin, Urinary bladder, Urinary Bladder, Overactive, business.industry, Age Factors, General Medicine, Middle Aged, medicine.disease, medicine.anatomical_structure, Tolerability, Overactive bladder, Female, business, medicine.drug |
| الوصف: | Overactive bladder (OAB) is a common condition whose prevalence increases with age. Antimuscarinic agents are the pharmacologic treatment of choice, but adverse events such as dry mouth may lead to early discontinuation. The purpose of this analysis was to compare the incidence and severity of dry mouth and other adverse events with solifenacin 5 mg/day and oxybutynin immediate release (IR) 15 mg/day in patients ≤ 65 years and65 years in the Canadian VECTOR study (VEsicare in Comparison To Oxybutynin for oveRactive bladder patients).VECTOR was a randomized, multicentre, prospective, double-blind, double-dummy study in 132 subjects with ≥ 1 urgency episode per 24 h, with or without urgency incontinence, and ≥ 8 micturitions per 24 h for ≥ 3 months. After a 2-week washout, patients received solifenacin 5 mg once daily or oxybutynin IR 5 mg tid for 8 weeks. For the current post-hoc analysis, adverse events were evaluated in subgroups of patients ≤ 65 years and65 years, using a full logistic regression model, multinomial logit regression model and reduced model.NCT00431041.The incidence and severity of dry mouth and other adverse events with solifenacin were similar between younger and older patients. In both age subgroups, solifenacin 5 mg/day was associated with fewer episodes and lower severity of dry mouth, and a lower discontinuation rate, compared with oxybutynin IR 15 mg/day.Solifenacin 5 mg/day was better tolerated than oxybutynin IR 15 mg/day in younger (≤ 65 years) and older (65 years) subgroups. Solifenacin was equally well tolerated in both age subgroups. Limitations of the analysis were that the study was not preplanned to perform post-hoc subgroup analysis, patients knew that dry mouth was a primary outcome, and the study used fixed doses of each drug. |
| تدمد: | 1473-4877 0300-7995 |
| الوصول الحر: | https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f6eb4f6b584b68000dd84daa076b8749Test https://doi.org/10.1185/03007995.2010.541433Test |
| رقم الانضمام: | edsair.doi.dedup.....f6eb4f6b584b68000dd84daa076b8749 |
| قاعدة البيانات: | OpenAIRE |
| تدمد: | 14734877 03007995 |
|---|